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Mechanical circulatory support devices, 
especially left ventricular assist devices 
(LVADs) represent an important treatment 
modality for patients with end-stage heart 
failure (HF). In a 1-year period (from Jan-
uary to December 2017) in our intensive 
care unit (ICU) we had a total of 8 patients 
with LVAD implantation. LVADs are de-
vices with unique physiology which restore 
tissue circulation by increasing blood sup-
ply, nevertheless, they can be challenging 
to manage and are associated with signifi-
cant complications. 
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INTRODUCTION
Mechanical circulatory support devices, 
especially left ventricular assist devices 
(LVADs) represent an important treatment 
modality for patients with end-stage heart 
failure (HF). Considering the shortage of 
donor organs, improvement in LVAD's 
technology and intensive care treatment 
modalities, the number of patients with 
LVAD implantation in intensive care units 
is increasing. Intensive care management 
of these patients requires an understand-
ing of the principles, indications, and limi-
tations of this unique technology, as well as 
a multidisciplinary approach (intensivists, 
cardiac surgeons, anesthesiologists, cardi-
ologists etc.) (1). 
Indications for LVAD implantation in-
clude: a) bridge to transplantation (BTT), 
b) bridge to decision (until a determina-
tion can be made regarding a patient’s eli-
gibility for cardiac transplantation), c) des-
tination therapy (DT) to support cardiac 
function for the remainder of a patient’s 
life and d) bridge to recovery (temporary 
support for patients whose cardiac func-
tion is expected to recover) (2).  
Older models of LVADs with pulsatile flow 
have been replaced with a newer genera-
tion of continuous-flow (CF) pumps which 
are smaller in size, more reliable, durable 
and subsequently lead to improvements 
in survival (3). Each LVAD consists of an 
inflow cannula positioned into the left ven-
tricular (LV) apex, a rotating element that 
imparts energy to the blood to increase 
arterial blood flow and pressure, an out-
flow cannula which directs blood into the 
ascending aorta and a controller with bat-
tery pack. 
 
PATIENTS AND PREOPERATIVE ICU 
MANAGEMENT
In a 1-year period (from January to De-
cember 2017) in our intensive care unit 
(ICU) we had a total of eight patients with 
LVAD implantation. Four patients had di-
lative ischemic cardiomyopathy with LVEF 
ranging from 15 to 25 % and were planned 
for LVAD implantation as DT. One patient 
had dilatative cardiomyopathy secondary 
to congenitally corrected transposition of 
the great arteries (dextrocardia was also 
present) who was on the transplant list but 
had NT (non-transplantable) status. LVAD 
exchange was planned in three patients 
due to microthrombosis of the LVAD in 
one case and infection of driveline in two 
cases. 
All patients planned for LVAD implan-
tation were admitted to our ICU the day 
before surgery for preoperative assessment 
and preparation. Arterial cannula for inva-
sive blood pressure monitoring, central ve-
nous catheter and pulmonary artery cathe-
ter with continuous cardiac output (CCO) 
and continuous mixed venous saturation 
(Sv02) monitoring were placed. Thereafter, 
we recorded basic hemodynamic param-
eters and their indexed values (IBP, CO, 
SV, SVR, PVR, PAP, PCWP, LVSW, RVSW, 
Sv02 and CVP) in all cases. There are in-
dications that preoperative use of levosi-
mendan (calcium sensitizer, inodilator) 
in patients eligible for LVAD implantation 
might improve clinical outcome and sur-
vival (4,5). 
Our protocol in this group of patients in-
cluded administration of a bolus dose of 
levosimendan (6 µg/kg i.v.) during 20 min-
utes and then as a continuous infusion (0.1 
µg/kg/h) during 24 hours. In all patients 
administration of levosimendan was safe 
and no clinically relevant side effects (sig-
nificant hypotension, arrhythmias) were 
observed. Positive effects of levosimendan 
include improvements in pre-implant 
hemodynamic performance (higher CI, 
lowering of PAP and CVP).  There is a lack 
of consensus on the regimen and duration 
of antibiotic prophylaxis during LVAD im-
plantation. In our ICU antibiotic prophy-
laxis for these cases consists of intravenous 
use of vancomycin, ciprofloxacin and flu-
conazole as well as oral (or via nasogastric 
tube) use of rifampicin. 
POSTOPERATIVE ICU MANAGEMENT 
AND POTENTIAL COMPLICATIONS
In all patients, the third generation of CF 
LVAD devices was implanted. Three pa-
tients received HeartWare (HeartWare 
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Inc.) and five patients received HeartMate 
III (Thoratec Corp.), magnetically levitated 
VAD with artificial pulse. In the postop-
erative period, a combination of inotropes, 
vasodilators and vasopressors were used in 
addition to correction of intravascular vol-
ume and speed adjustments for optimizing 
hemodynamic parameters. Maintenance 
of adequate intravascular volume is of 
great importance because these pumps are 
preload dependent and inadequate filling 
will result in low pump flow. LVAD vari-
ables such as pump speed (in RPMs) which 
is the only variable programmed by the op-
erator and other variables which depend 
on the patient’s underlying physiology; 
pump flow (L/m), pump power (W) and 
pulsatility index1 are recorded regularly. 
Cardiac ultrasonography (TTE or TEE) is 
very helpful for assessing hemodynamic 
parameters in LVAD patients, particularly 
in evaluation of RV size and function, sep-
tal positioning (it should be flat and neu-
tral), LV size and function, preload, signs 
of pericardial effusion or tamponade, posi-
tion of the cannulas and competency of the 
aortic valve (it should be competent and 
open intermittently, every second or third 
beat) (6). After thorough ultrasonographic 
assessment, optimal pump speed can be 
determined. 
Also, these devices are sensitive to excess 
afterload (CF devices to a greater extent 
than axial flow devices) so careful moni-
toring of MAP and SVR should be done 
(7). According to the International Soci-
ety of Heart and Lung Transplant (ISHLT) 
guidelines, MAP in patients supported by 
CF-LVADs should be less than or equal to 
80 mm Hg (8). Also, MAP shouldn't be 
too low to avoid hypoperfusion of the RV, 
kidneys and gut. On the other hand, exces-
sive blood pressure can lead to neurologic 
events, bleeding, and reduced flow of the 
LVAD (1).  In many patients, CF-LVADs 
are associated with a reduced pulse pres-
sure, and the degree of this diminished 
pulsatility depends on the pump speed set-
ting, underlying LV contractility, preload, 
afterload pressures7 and presence and 
degree of aortic valve opening. Therefore, 
on physical examination, patients with CF 
devices may not have palpable pulses so it 
can be difficult to place an arterial cannula 
for IBP and may require ultrasonographic 
guidance. 
Existing anticoagulation protocols for 
LVAD vary by institution, device and in-
dividual patient. Our protocol begins with 
starting unfractioned heparin (UHF) 12-
24 hours after surgery if chest tube drain-
age is less than 50 ml during a 2-3 hour 
period and titrating it to achieve a partial 
thromboplastin time (PTT) of 45-50 sec-
onds (1.2-1.4 x control). After 24-48 hours, 
UHF dosing needs to be increased and ti-
trated to a PTT of 50-60 seconds (1.4-1.7 x 
control) and after 48–72 hours PTT values 
should be 55-65 seconds (1.5-1-8 x con-
trol). Aspirin is initiated on the second or 
third postoperative day. Once there is no 
evidence of bleeding and the chest tubes 
have been removed, warfarin can be start-
ed (overlapping with UHF). UHF can safe-
ly be removed after an acceptable, stable 
INR (2.0-3.0) is obtained. Anticoagulation 
protocols often differ from the one shown 
due to unexpected hemorrhage and/or dif-
ferent sensitivity of individual patients to 
administered drugs. 
Postoperative complications include, but 
are not limited to: bleeding, RV failure, ar-
rhythmias, infections, thrombosis, neuro-
logic events and hemolysis. Postoperative 
management of LVAD patients requires a 
careful balance between the risks of hem-
orrhage and thrombosis because both 
procoagulant and anticoagulant pathways 
are activated in patients on LVAD support 
(9). Bleeding is the most frequent adverse 
event in the postoperative period and early 
bleeding requiring surgery is seen in 26% 
of patients (10,11). Like in other types of 
cardiac surgery, one should always try to 
recognize cardiac tamponade as it requires 
emergent surgical revision. Regular moni-
toring of laboratory parameters including 
prothrombin time, partial thromboplastin 
time, platelet count and fibrinogen levels 
guide the administration of platelets, fresh 
frozen plasma, and cryoprecipitate. Factor 
VII should be used cautiously in patients 
with LVADs given the potential for serious 
thromboembolic events, particularly at 
higher doses (12).
Patients with prior cardiac surgery expe-
rience longer cardiopulmonary bypass 
(CPB) time and more postoperative bleed-
ing (13). One patient died in the early 
postoperative period (eight hours after 
surgery) due to a combination of excessive 
surgical bleeding and coagulopathy (DIC). 
Other forms of bleeding include epistaxis, 
GI bleeding (continuous blood flow may 
lead to formation of AV malformations) 
and intracranial hemorrhage (particularly 
with excessively high LVAD flows and 
MAP> 90 mmHg). Estimates of the inci-
dence of right-sided HF after placement of 
an LVAD vary in literature (5 to 40%, de-
pending on criteria of RV failure) and are 
associated with marked deterioration of 
survival prospects. Numerous predictors 
of post-LVAD RV failure have been identi-
fied like elevated CVP or CVP/PCWP ra-
tio, severe renal dysfunction and ventilator 
dependence.14 Specific echocardiographic 
measures of RV function have exhibited 
poor reproducibility across studies. After 
LVAD implantation, RV geometry changes 
as the septum shifts to the left with LV un-
loading, causing an increase in RV compli-
ance but a decrease in contractility. Venous 
return is increased due to improved CO 
from the LVAD, but right ventricular af-
terload may remain high due to increased 
PAP.1 Maintaining the septum in its nor-
mal position can be done by carefully mon-
itoring volume status, doses of inotropes, 
and device settings after echocardiography 
assessment.  Too high of a pump speed will 
shift the septum leftward (causing impair-
ment in RV function), too low of a pump 
speed will shift the septum rightward and 
cause increased LA pressure which also 
impairs RV function.15 In the postopera-
tive period it is prudent to maintain a MAP 
>70 mmHg to preserve RV and this often 
requires use of one or more vasopressors 
(norepinephrine, vasopressin) (2). Factors 
which increase PVR such as hypercarbia, 
hypoxia, high airway pressures and levels 
of PEEP, also need to be avoided.  One pa-
tient in our ICU presented with RV failure 
after LVAD implantation, presumably due 
to septic shock and showed no signs of re-
covery despite high inotropic support, an-
tibiotics and other modalities of intensive 
care treatment. 
Both atrial and ventricular arrhythmias 
are common post-LVAD implantation. 
Although rapid atrial arrhythmias can be 
tolerated initially, loss of AV synchrony 
results in reduced ventricular filling and 
decompensated RV failure and patients 
may therefore require rate or rhythm con-
trol (16). Ventricular arrhythmias can be 
triggered by contact between the inflow 
cannula and the ventricular septum dur-
ing suction events usually caused by hypo-
volemia, too high of an LVAD speed, RV 
failure or small ventricular size (1). There-
fore the speed should be set to avoid ex-
cessive ventricular unloading and volume 
status optimized if needed.  
LVAD patients in cardiac arrest should 
be managed with the Advanced Cardiac 
Life Support (ACLS) algorithm for car-
diac arrest with a few exceptions. Most 
importantly, chest compressions are not 
recommended due to potential dislodge-
ment of the device or its outflow cannula 
located directly beneath the sternum, in 
which case massive hemorrhage can oc-
cur.  In this group of patients, infection 
(VAD-specific, VAD-related, non-VAD 
infections) is the second most common 
cause of death after cardiac failure (17). 
Our three patients after LVAD implanta-
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tion died of sepsis and multiple organ fail-
ure (MOF). The incidence of acute kidney 
injury (AKI) after LVAD implantation has 
been reported to range from 7 to 56 % with 
the large variation in range likely due to 
differing definitions for AKI (6). Criteria 
for renal replacement therapy are the same 
for patients with or without LVADs. Our 
one patient with LVAD required CVVHDF 
in the early postoperative period within a 
clinical picture of septic shock and MOF. 
Major thrombotic events in LVAD patients 
include pump thrombosis and arterial 
thromboembolism. Thrombi form on the 
impeller or areas of low flow, such as the 
aortic valve, atrial appendage, or a dilated 
LV.1 Device thrombosis can develop even 
when patients are fully anticoagulated 
and taking adequate antiplatelet therapy 
because the LVAD causes a chronic hy-
percoagulable state (6). One patient came 
for LVAD exchange due to late device mi-
crothrombosis (2 years after initial LVAD 
implantation), but we did not notice any 
thrombotic complications during the post-
operative period in the ICU.
With the introduction of CF devices, the 
incidence of stroke in patients with LVADs 
has decreased substantially; however, pa-
tients remain at a high risk for stroke. Is-
chemic strokes occur in about 8–10% of 
LVAD patients (18). One patient in our 
ICU had a transient neurological disorder 
with disorientation after LVAD placement, 
but without pathology on CT scan. He-
molysis is present in about 4-18% of pa-
tients with pulsatile or CF- LVAD (18,19). 
Results of laboratory tests that reveal evi-
dence of hemolysis are LDH levels greater 
than 3 x the upper limit of normal, elevated 
bilirubin and plasma free hemoglobin and 
low levels of haptoglobin. Hemolysis can 
be various in origin (sign of pump throm-
bosis, result of too high inlet velocities or 
can be transfusion related) (20).
 
DISCUSSION
The overall rate of LVAD implantation in-
creases every year, especially the number 
of LVADs for DT. Generally, all patients 
planned for LVAD implantation are high 
risk patients with deteriorated hemody-
namic status and lots of comorbidities. 
Several risk factors for early mortality after 
LVAD implantation have been identified 
including advanced age, female gender, 
obesity, INTERMACS profile 1–2, renal 
dysfunction, elevated bilirubin and pre-
vious cardiac surgery. Of our eight pa-
tients, seven were male with an age range 
from 61–72 years and one was a female 
and 54 years of age. All of them were IN-
TERMACS 2 profile before surgery and 
had significant comorbidities (including 
hypertension, pulmonary hypertension, 
diabetes mellitus, renal insufficiency etc.). 
Our four patients had one previous cardiac 
surgery (CABG, valve surgery or LVAD 
implantation) and in one patient who un-
derwent LVAD exchange this was their 
third cardiac procedure.  In our patients, 
mortality was high due to various causes. 
One patient died in the operating theatre 
due to inability to wean from CPB (low 
cardiac output syndrome and vasoplegia), 
three patients died from septic complica-
tions (7, 10 and 11 day after surgery) and 
one patient died from postoperative hem-
orrhage eight hours after surgery. In the 
postoperative period LVAD patients re-
quire respiratory and hemodynamic sup-
port, broad spectrum antibiotics, regular 
assessment of volume status and heart 
function, frequent laboratory parameters 
testing and meticulous attention to bleed-
ing. Once again it should be emphasized 
that anticoagulation protocols are of great 
importance but a "one size fits all" protocol 
does not exist.
To conclude, LVADs are devices with 
unique a physiology which restores tissue 
circulation by increasing blood supply, 
nevertheless, they can be challenging to 




LVEF – left ventricular ejection fraction
IBP – invasive blood pressure
CO – cardiac output
SV – stroke volume
SVR – systemic vascular resistance
PVR – pulmonary vascular resistance
PAP – pulmonary arterial pressure
PCWP – pulmonary capillary wedge pres-
sure
LVSW – left ventricular stroke work 
RVSW – right ventricular stroke work
Sv02 – mixed venous saturation
CVP – central venous pressure
CI – cardiac index
RPM - revolutions per minute
TTE - transthoracic echocardiography
TEE- transesophageal echocardiography
MAP – mean arterial pressure
RV – right ventricle
INR - international normalized ratio
DIC – disseminated intravascular coagu-
lopathy
LA – left atrial
PEEP – peak end expiratory pressure
INTERMACS - Interagency Registry for 
Mechanically Assisted Circulatory Support
CABG - Coronary Artery Bypass Grafting
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